BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 19856481)

  • 1. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
    Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
    J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Structural analysis of the PKR-binding region of HCV 1b samples from patients with chronic hepatitis C and the correlation with IFN-sensitivity].
    Gervain J; Czibula A; Simon J; Kalmár T
    Orv Hetil; 2003 Jun; 144(24):1179-84. PubMed ID: 12866147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Association between NS5A gene sequence and response to interferon therapy in chronic hepatitis C patients in Shanghai].
    Hu Y; Tang M; Jiang W; Wu Y; Yuan Z; Wen Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Jun; 16(2):114-8. PubMed ID: 12196819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes.
    Frangeul L; Cresta P; Perrin M; Lunel F; Opolon P; Agut H; Huraux JM
    Hepatology; 1998 Dec; 28(6):1674-9. PubMed ID: 9828234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.
    Murayama M; Katano Y; Nakano I; Ishigami M; Hayashi K; Honda T; Hirooka Y; Itoh A; Goto H
    J Med Virol; 2007 Jan; 79(1):35-40. PubMed ID: 17133546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
    Zeuzem S; Lee JH; Roth WK
    Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon sensitivity-determining region of nonstructural region 5A of hepatitis C virus genotype 1b correlates with serum alanine aminotransferase levels in chronic infection.
    Yoshioka K; Ito H; Watanabe K; Yano M; Ishigami M; Mizutani T; Sasaki Y; Goto H
    J Viral Hepat; 2005 Mar; 12(2):139-45. PubMed ID: 15720528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Murphy MD; Rosen HR; Marousek GI; Chou S
    Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein.
    Fukuma T; Enomoto N; Marumo F; Sato C
    Hepatology; 1998 Oct; 28(4):1147-53. PubMed ID: 9755255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of clinical evidence for involvement of hepatitis C virus interferon-alpha sensitivity-determining region variability in RNA-dependent protein kinase-mediated cellular antiviral responses.
    Mihm S; Monazahian M; Grethe S; Meier V; Thomssen R; Ramadori G
    J Med Virol; 2000 May; 61(1):29-36. PubMed ID: 10745229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
    Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
    J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence diversity of hepatitis C virus 6a within the extended interferon sensitivity-determining region correlates with interferon-alpha/ribavirin treatment outcomes.
    Zhou DX; Chan PK; Zhang T; Tully DC; Tam JS
    Virus Res; 2010 Oct; 153(1):44-9. PubMed ID: 20624431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
    Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.
    Hofmann WP; Zeuzem S; Sarrazin C
    J Clin Virol; 2005 Feb; 32(2):86-91. PubMed ID: 15653410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
    Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
    El-Shamy A; Shoji I; Saito T; Watanabe H; Ide YH; Deng L; Kawata S; Hotta H
    Microbiol Immunol; 2011 Jun; 55(6):418-26. PubMed ID: 21371092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon.
    Kobayashi M; Watanabe K; Ishigami M; Murase K; Ito H; Ukai K; Yano M; Takagi K; Hattori M; Kakumu S; Yoshioka K
    Am J Gastroenterol; 2002 Apr; 97(4):988-98. PubMed ID: 12003437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
    El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
    PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.
    Yen YH; Hung CH; Hu TH; Chen CH; Wu CM; Wang JH; Lu SN; Lee CM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):72-9. PubMed ID: 17973647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.